Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

673 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
Stein EM, DiNardo CD, Fathi AT, Mims AS, Pratz KW, Savona MR, Stein AS, Stone RM, Winer ES, Seet CS, Döhner H, Pollyea DA, McCloskey JK, Odenike O, Löwenberg B, Ossenkoppele GJ, Patel PA, Roshal M, Frattini MG, Lersch F, Franovic A, Nabhan S, Fan B, Choe S, Wang H, Wu B, Hua L, Almon C, Cooper M, Kantarjian HM, Tallman MS. Stein EM, et al. Among authors: dohner h. Blood. 2021 Apr 1;137(13):1792-1803. doi: 10.1182/blood.2020007233. Blood. 2021. PMID: 33024987 Free PMC article. Clinical Trial.
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.
Fröhling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K, Döhner H, Döhner K; AML Study Group Ulm. Acute myeloid leukemia. Fröhling S, et al. Among authors: dohner k, dohner h. Blood. 2002 Dec 15;100(13):4372-80. doi: 10.1182/blood-2002-05-1440. Epub 2002 Aug 8. Blood. 2002. PMID: 12393388 Free article.
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.
Fiedler W, Serve H, Döhner H, Schwittay M, Ottmann OG, O'Farrell AM, Bello CL, Allred R, Manning WC, Cherrington JM, Louie SG, Hong W, Brega NM, Massimini G, Scigalla P, Berdel WE, Hossfeld DK. Fiedler W, et al. Among authors: dohner h. Blood. 2005 Feb 1;105(3):986-93. doi: 10.1182/blood-2004-05-1846. Epub 2004 Sep 30. Blood. 2005. PMID: 15459012 Free article. Clinical Trial.
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.
Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, Siehl S, Jäger U, Bergmann M, Stilgenbauer S, Schweighofer C, Wendtner CM, Döhner H, Brittinger G, Emmerich B, Hallek M; German CLL Study Group. Eichhorst BF, et al. Among authors: dohner h. Blood. 2006 Feb 1;107(3):885-91. doi: 10.1182/blood-2005-06-2395. Epub 2005 Oct 11. Blood. 2006. PMID: 16219797 Free article. Clinical Trial.
Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemia.
Zenz T, Ritgen M, Dreger P, Kröber A, Barth TF, Schlenk R, Böttcher S, Hallek MJ, Kneba M, Bunjes D, Döhner H, Stilgenbauer S. Zenz T, et al. Among authors: dohner h. Blood. 2006 Sep 15;108(6):2127-30. doi: 10.1182/blood-2006-04-007898. Epub 2006 May 25. Blood. 2006. PMID: 16728696 Free article. Clinical Trial.
Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B.
Fröhling S, Schlenk RF, Kayser S, Morhardt M, Benner A, Döhner K, Döhner H; German-Austrian AML Study Group. Fröhling S, et al. Among authors: dohner k, dohner h. Blood. 2006 Nov 15;108(10):3280-8. doi: 10.1182/blood-2006-04-014324. Epub 2006 Jul 13. Blood. 2006. PMID: 16840728 Free article. Clinical Trial.
Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib.
Heidel F, Cortes J, Rücker FG, Aulitzky W, Letvak L, Kindler T, Huber C, Döhner H, Kantarjian H, Fischer T. Heidel F, et al. Among authors: dohner h. Cancer. 2007 Mar 1;109(5):907-14. doi: 10.1002/cncr.22471. Cancer. 2007. PMID: 17285599 Free article. Clinical Trial.
673 results